In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent …
Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering …
Amid Novartis’ strategic review of generics unit Sandoz, last month came word that Swedish investment group EQT and the Struengmann brothers of Germany were considering …
China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
